MAP2K1 and neoplasm: As a consequence, treatment with the Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) inhibitor trametinib releases transcriptional stalling at the MYF4 promoter, followed by a widespread MYF4-induced change in SE landscape, myogenic differentiation and reduced tumor growth in mouse models [186].